Cipla Limited

Cipla Limited

Cipla Limited has informed the Exchange about the link of recording of earnings conference call for the quarter ended 30th June, 2026, available on the Company’s website.

Cipla Limited

Cipla Limited has informed the Exchange that the Board has approved the changes in the Key Managerial Personnels (KMPs) and Officers authorised under Regulation 30(5) of the SEBI Listing Regulations.

Cipla Limited

Cipla Limited has informed the Exchange regarding the grant of stock options and employee stock appreciation rights under the Employee Stock Option Scheme 2013 A and the Cipla Employee Stock Appreciation Rights Scheme 2021.

Cipla Limited

Cipla Limited has informed the Exchange about change in management. Mr. Sanjay Joseph, Head – API Business, will cease to be Senior Managerial Personnel (SMP) with effect from 24th July, 2026.

Cipla Limited

Cipla Limited has informed the Exchange regarding Outcome of Board Meeting held on July 23, 2026. The Board of Directors has approved the transition of Mr. Ashish Adukia to an internal business leadership role, and the appointment of Mr. Dinesh Jain as Global Chief Financial Officer.

Cipla Limited

Cipla Limited has announced its Q1 FY27 results, with revenue of INR 7,119 Cr, a 2% YoY growth, and EBITDA of INR 1,192 Cr, a 16.7% of income from operations. The company's One-India business grew at 12% YoY, while North America delivered quarterly revenue of $162 Mn. The company's net cash position is INR 9,494 Cr, with debt primarily consisting of lease liabilities and working capital requirements.

Cipla Limited

Cipla Limited has informed the Exchange about Investor Presentation. The presentation highlights the company's Q1FY27 performance, with revenue of INR 7,119 Cr, EBITDA of INR 1,192 Cr, and PAT of INR 789 Cr. The company has maintained its leadership in the chronic market and has launched new products, including Yurpeak, Duolin Syncrobreathe, and Doloneuron. The presentation also discusses the company's strategic focus on therapeutic areas such as respiratory, urology, anti-diabetes, and cardiac.

Cipla Limited

Cipla Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of ₹785.55 crores and earnings per equity share of ₹9.77.

Cipla Limited

Cipla Limited has informed the Exchange about a USFDA inspection at its InvaGen manufacturing facility in Central Islip, Long Island, NY, USA, which resulted in 1 inspectional observation in Form 483.

Cipla Limited

Cipla Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2026.

Cipla Limited

Cipla Limited has received an ESG rating from Crisil ESG Ratings & Analytics Limited, with ratings of 'Crisil ESG 69' and 'Crisil Core ESG 66'.

Cipla Limited

Cipla Limited has announced the schedule of its Earnings Conference Call to be held on July 23, 2026, to discuss its Q1FY27 unaudited Financial Results.

Cipla Limited

Cipla Limited has issued a corrigendum to the transcript of the 90th Annual General Meeting, correcting a few typographical errors.

Cipla Limited

Cipla Limited held its 90th Annual General Meeting through video conferencing on June 25, 2026, with a transcript uploaded on the company's website. The meeting was attended by directors, management, and auditors, and the proceedings were recorded for transparency.

Cipla Limited

Cipla Limited has informed the Exchange about Newspaper Publication regarding opening of special window for lodgement of transfer and dematerialisation of physical shares.

Cipla Limited

Cipla Limited has informed the Exchange regarding Change in Auditors of the company. The members of the Company at the 90th Annual General Meeting (AGM) held today, have approved the appointment of M/s B S R & Co. LLP, Chartered Accountants as the Statutory Auditors of the Company, for a term of five (5) consecutive years with effect from the conclusion of the 90th AGM till the conclusion of the 95th AGM.

Cipla Limited

Cipla Limited has held its 90th Annual General Meeting (AGM) on June 25, 2026, through video conferencing. The meeting was attended by Dr. Y K Hamied, Chairman, and Mr. Achin Gupta, Managing Director and Global Chief Executive Officer. The AGM proceedings, speech, and presentation are available on the company's website.

Cipla Limited

Cipla Limited has submitted the Exchange a copy of the Scrutinizer's report of the 90th Annual General Meeting held on June 25, 2026, and informed the Exchange regarding voting results.

Cipla Limited

Cipla Limited has informed the Exchange about ESG Rating revision from 68 to 64 by ESGRisks.ai, a SEBI registered ESG Rating Provider.

Cipla Limited

Cipla Limited announced that Dr. Y. K. Hamied has submitted a disclosure to the exchange under Regulations 31(4) and 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. These regulations typically require promoters or significant shareholders to disclose details regarding encumbered shares or changes in their shareholding. While the full content of the disclosure is not detailed in this announcement, such filings are crucial for maintaining transparency in the company's ownership structure. This ensures investors are informed about potential changes in promoter holdings or control, which can be significant for their investment decisions.